Clinical pharmacokinetics of toremifene

Clinical Pharmacokinetics

Volumn 39, Issue 5, 2000, Pages 327-334

  Taras, Tracy L ^a   Wurz, Gregory T ^a   Linares, Gabriel R ^a   DeGregorio, Michael W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DOXORUBICIN; TAMOXIFEN DERIVATIVE; TOREMIFINE; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ANTINEOPLASTIC ACTIVITY; BIOAVAILABILITY; BREAST CANCER; DRUG ELIMINATION; DRUG STRUCTURE; DRUG TOLERABILITY; ENTEROHEPATIC CIRCULATION; HOT FLUSH; HUMAN; NAUSEA; PRIORITY JOURNAL; REVIEW; STEADY STATE; VAGINA DISCHARGE; VOMITING;

EID: 0033678649     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200039050-00002     Document Type: Review

References (26)

1. Toremifene: A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer
2. Tamoxifen and toremifene in breast cancer: Comparison of safety and efficacy
3. Phase III trials of toremifene vs tamoxifen
4. Interim results of the Finnish toremifene vs. tamoxifen adjuvant trial
5. Hormone replacement therapy and breast cancer: Revisiting the issues
6. Comparison of the effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients
7. Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer
8. Selective estrogenic effects of a novel triphenylethylene compound FC1271a on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats
9. Adjuvant trials of toremifene versus tamoxifen: The European experience
10. Toremifene: Pharmacologic and pharmacokinetic basis of reversing multidrug resistance
11. Tissue distribution of transdermal toremifene
12. Intratumoral toremifene therapy and tissue distribution in the baboon
13. Pharmacokinetics of toremifene
14. A phase I study of toremifene
15. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer
16. Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer
17. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin
18. Influence of age on toremifene pharmacokinetics
19. Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function
20. Pharmacokinetics of anti-endocrine agents
21. Binding of toremifene to human serum proteins
22. 11C-toremifene in rats bearing DMBA-induced mammary carcinoma
23. Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes
24. Biochemical and pharmacological effects of toremifene metabolites
25. Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin
26. Targeting chemosensitizing doses of toremifene based on protein binding